At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
mogamulizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Multicenter Phase 1 Study of Mogamulizumab (KW-0761) in Combination With Docetaxel in Previously Treated Subjects With Non-small Cell Lung Cancer (NSCLC)
In Brief
A Phase 1 clinical trial evaluating mogamulizumab and Docetaxel for Non-Small Cell Lung Cancer. Completed, enrolled 13 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate the safety of mogamulizumab in combination with docetaxel in adult subjects with previously treated locally advanced or metastatic non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedFeb 2015
Primary CompletionDec 2016
TodayJul 2026
First PostedFeb 9, 2015
Enrollment StartJan 1, 2015
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.4 years ago
Interventions
mogamulizumabbiological
Mogamulizumab will be administered by IV infusion.
Docetaxeldrug
Docetaxel will be administered by IV infusion.